Skip to content
HowShorted

Corvus Pharmaceuticals, Inc. short interest in 2021

In 2021, Corvus Pharmaceuticals, Inc.'s disclosed short interest ran from 4.40% of shares outstanding on 15 Jan 2021 to 0.48% on 31 Dec 2021, a change of -3.92 percentage points. The year's high was 5.64% on 15 Mar 2021 and its low 0.48% on 31 Dec 2021, averaging 3.11% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.04 days on 30 Apr 2021. Full history: Corvus Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corvus Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
4.40% (15 Jan 2021)
End of year
0.48% (31 Dec 2021)
Change
-3.92 pp
High
5.64% (15 Mar 2021)
Low
0.48% (31 Dec 2021)
Average
3.11%
Highest days to cover
8.04 (30 Apr 2021)
SEC filings marked
10

Every report in 2021

Corvus Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20214.40%7.95
29 Jan 20214.39%5.55
12 Feb 20214.41%1.79results (8-K)
26 Feb 20214.54%1.00
15 Mar 20215.64%1.95
31 Mar 20213.79%2.8910-K filed, results (8-K)
15 Apr 20213.50%5.73
30 Apr 20213.44%8.0410-Q filed, results (8-K)
14 May 20213.13%1.45
28 May 20213.24%5.58
15 Jun 20212.96%7.58
30 Jun 20213.16%6.16
15 Jul 20213.19%6.41results (8-K)
30 Jul 20213.29%3.54
13 Aug 20212.30%4.4010-Q filed, results (8-K)
31 Aug 20211.20%2.60
15 Sep 20211.73%2.57
15 Oct 20214.19%1.00
29 Oct 20214.34%2.81
15 Nov 20212.25%1.0910-Q filed, results (8-K)
30 Nov 20211.22%1.00
15 Dec 20210.70%1.00
31 Dec 20210.48%1.00

See also: Corvus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.